Cardiac Arrhythmia: Possible Complication from Treatment with Cisplatin

Cardiotoxicity is rarely observed during cisplatin chemotherapy. A possible synergistic toxic effect of cisplatin with etoposide on cardiac electrical activity is discussed. A case of a 60-year-old woman with squamous cell lung carcinoma who developed paroxysmal supraventricular tachycardia during cisplatin chemotherapy is reported. The potential cardiotoxicity should be considered when cisplatin is combined with other cardiotoxic agents or used in patients with cardiac disease.

[1]  Z. Ruciński.  [Myocardial infarction in a 27-year-old woman]. , 1988, Wiadomosci lekarskie.

[2]  N. Kantrowitz,et al.  Cardiotoxicity of antitumor agents. , 1984, Progress in cardiovascular diseases.

[3]  A. Scanni,et al.  Ischemic Cardiopathy from CIS-Diamminedichloroplatinum (CDDP) , 1984, Tumori.

[4]  P. Salem,et al.  Supraventricular tachycardia. A probable complication of platinum treatment. , 1984, Oncology.

[5]  M. Bristow.  Cardiotoxic effects of anthracyclines. , 1983, The Western journal of medicine.

[6]  J. Mason,et al.  Efficacy and cost of cardiac monitoring in patients receiving doxorubicin , 1982, Cancer.

[7]  W. Looney,et al.  Cyclophosphamide-induced cardiomyopathy in the rat. , 1982, Cancer treatment reports.

[8]  N. Niederle,et al.  Etoposide--chemistry, preclinical and clinical pharmacology. , 1982, Cancer treatment reviews.

[9]  H. Schmoll.  Review of etoposide single-agent activity. , 1982, Cancer treatment reviews.

[10]  J. Kleinerman,et al.  Interaction of Adriamycin in Vitro with Cardiac Myofibrillar Proteins , 1982, Circulation research.

[11]  S. Wallace,et al.  Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. , 1982, Annals of internal medicine.

[12]  I. Shapira,et al.  [5-fluorouracil cardiotoxicity]. , 1982, Harefuah.

[13]  J. Mason,et al.  Dose-effect and structure-function relationships in doxorubicin cardiomyopathy. , 1981, American heart journal.

[14]  F. Villani,et al.  5-Fuorouracil Cardiotoxicity , 1979, Tumori.

[15]  R. W. Roberts,et al.  Cyclophosphamide‐induced cardiomyopathy. A report of two cases and review of the english literature , 1979, Cancer.

[16]  M. Ravry.  Cardiotoxicity of mitomycin C in man and animals. , 1979, Cancer treatment reports.

[17]  J. Mason,et al.  Anthracycline cardiomyopathy monitored by morphologic changes. , 1978, Cancer treatment reports.

[18]  J. Mason,et al.  Doxorubicin cardiomyopathy: evaluation by phonocardiography, endomyocardial biopsy, and cardiac catheterization. , 1978, Annals of internal medicine.

[19]  A. Weiss,et al.  Experience with the use of adriamycin in combination with other anticancer agents using a weekly schedule, with particular reference to lack of cardiac toxicity , 1977, Cancer.

[20]  D. Mikhailidis,et al.  CARDIOTOXICITY OF 5-FLUOROURACIL , 1977, The Lancet.

[21]  G. Somers,et al.  MYOCARDIAL INFARCTION: A COMPLICATION OF VINCRISTINE TREATMENT? , 1976, The Lancet.

[22]  R. Jaenke.  Delayed and progressive myocardial lesions after adriamycin administration in the rabbit. , 1976, Cancer research.

[23]  I. Mccoll,et al.  5-FLUOROURACIL AND ANGINA , 1975, The Lancet.

[24]  J. Pinkhas,et al.  Endocardial fibrosis following busulfan treatment. , 1975, JAMA.

[25]  M. Berenbaum,et al.  Cardiac and pulmonary effects of high doses of cyclophosphamide and isophosphamide. , 1974, Cancer research.

[26]  B. Carr,et al.  cis-Platinum (II) Diamminedichloride , 1974 .

[27]  J. Gutterman,et al.  Clinical evaluation of toxic effects of cis-diamminedichloroplatinum (NSC-119875)--phase I clinical study. , 1973, Cancer chemotherapy reports.

[28]  J. Pitha,et al.  A clinicopathologic analysis of adriamycin cardiotoxicity , 1973, Cancer.

[29]  R. Davis,et al.  cis-Dichlorodiammineplatinum(II) (NSC-119 875): preclinical toxicologic evaluation of intravenous injection in dogs, monkeys and mice. , 1973, Toxicology and applied pharmacology.